Jesús Camino

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Duration of Antibiotic Treatment in Community-Acquired Pneumonia

Ane Uranga, Pedro Pablo España, Amaia Bilbao et al. · JAMA Internal Medicine · 2016 · 290 citations · Full text

Pharmacy, Infectious Diseases, Internal Medicine +13

Escherichia coli: An unknown and infrequent cause of community acquired pneumonia

Luis Alberto Ruiz, Rafael Zalacaín, Ainhoa Gómez et al. · Scandinavian Journal of Infectious Diseases · 2008 · 12 citations

Life Sciences, Infectious Diseases, Microbiology +16

Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia

Ane Uranga, Amaia Artaraz, Amaia Bilbao et al. · BMC Pulmonary Medicine · 2020 · 12 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13